Human papillomavirus typing in reporting of condyloma

Sexually Transmitted Diseases

Volumn 40, Issue 2, 2013, Pages 123-129

  Sturegard, Erik ^a   Johansson, Hanna ^b   Ekström, Johanna ^b   Hansson, Bengt Göran ^a   Johnsson, Annika ^c   Gustafsson, Eva ^d   Dillner, Joakim ^a,e   Forslund, Ola ^a  

^a Lund University   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d Regional Department of Infectious Disease Control and Prevention   (Sweden)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CONDYLOMA; FEMALE; GENE AMPLIFICATION; GENOME SIZE; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; OUTPATIENT DEPARTMENT; SEX DIFFERENCE; UTERINE CERVIX CANCER; VACCINATION; VIRUS DETECTION; VIRUS TYPING; WART VIRUS;

ADOLESCENT; AGED; ALPHAPAPILLOMAVIRUS; CONDYLOMATA ACUMINATA; FEMALE; GENOTYPING TECHNIQUES; HUMAN PAPILLOMAVIRUS 11; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMAN PAPILLOMAVIRUS 6; HUMANS; MALE; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PILOT PROJECTS; POPULATION SURVEILLANCE; PUBLIC HEALTH; SWEDEN; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84872906249     PISSN: 01485717     EISSN: 15374521     Source Type: Journal    
DOI: 10.1097/OLQ.0b013e31827aa9b3     Document Type: Article

References (30)

1. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189:12-19.
2. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348:518-527.
3. Ball SL, Winder DM, Vaughan K, et al. Analyses of human papillomavirus genotypes and viral loads in anogenital warts. J Med Virol 2011; 83:1345-1350.
4. Brown DR, Schroeder JM, Bryan JT, et al. Detection of multiple human papillomavirus types in condylomata acuminata lesions from otherwise healthy and immunosuppressed patients. J Clin Microbiol 1999; 37:3316-3322.
5. Gissmann L, deVilliers EM, zur Hausen H. Analysis of human genital warts (condylomata acuminata) and other genital tumors for human papillomavirus type 6 DNA. Int J Cancer 1982; 29:143-146.
6. Gissmann L, Wolnik L, Ikenberg H, et al. Human papillomavirus types 6 and 11 DNA sequences in genital and laryngeal papillomas and in some cervical cancers. Proc Natl Acad Sci U S A 1983; 80:560-563.
7. Gross G, Ikenberg H, Gissmann L, et al. Papillomavirus infection of the anogenital region: Correlation between histology, clinical picture, and virus type. Proposal of a new nomenclature. J Invest Dermatol 1985; 85:147-152.
8. Hagiwara M, Sasaki H, Matsuo K, et al. Loop-mediated isothermal amplification method for detection of human papillomavirus type 6, 11, 16, and 18. J Med Virol 2007; 79:605-615.
9. Lowhagen GB, Bolmstedt A, Ryd W, et al. The prevalence of ''high-risk'' HPV types in penile condylomaYlike lesions: Correlation between HPV type and morphology. Genitourin Med 1993; 69:87-90.
10. Meyer T, Arndt R, Christophers E, et al. Association of rare human papillomavirus types with genital premalignant and malignant lesions. J Infect Dis 1998; 178:252-255.
11. Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356:1915-1927.
12. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: An interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369:2161-2170.
13. Pathirana D, Hillemanns P, Petry KU, et al. Short version of the German evidence-based guidelines for prophylactic vaccination against HPV-associated neoplasia. Vaccine 2009; 27:4551-4559.
14. Dillner J, Kjaer SK, Wheeler CM, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: Randomised controlled trial. BMJ 2010; 341:c3493.
15. Winer RL, Kiviat NB, Hughes JP, et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis 2005; 191:731-738.
16. Fairley CK, Hocking JS, Gurrin LC, et al. Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex Transm Infect 2009; 85:499-502.
17. Donovan B, Franklin N, Guy R, et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: Analysis of national sentinel surveillance data. Lancet Infect Dis 2011; 11:39-44.
18. Ferguson M, Wilkinson DE, Zhou T. WHO meeting on the standardization of HPVassays and the role of the WHO HPV Laboratory Network in supporting vaccine introduction held on 24-25 January 2008, Geneva, Switzerland. Vaccine 2009; 27:337-347.
19. Fazel N, Wilczynski S, Lowe L, et al. Clinical, histopathologic, and molecular aspects of cutaneous human papillomavirus infections. Dermatol Clin 1999; 17:521-536, viii.
20. de Roda Husman AM, Walboomers JM, van den Brule AJ, et al. The use of general primers GP5 and GP6 elongated at their 3¶ ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol 1995; 76:1057-1062.
21. Soderlund-Strand A, Carlson J, Dillner J. Modified general primer PCR system for sensitive detection of multiple types of oncogenic human papillomavirus. J Clin Microbiol 2009; 47:541-546.
22. Schmitt M, Bravo IG, Snijders PJ, et al. Bead-based multiplex genotyping of human papillomaviruses. J Clin Microbiol 2006; 44: 504-512.
23. Forslund O, Antonsson A, Nordin P, et al. A broad range of human papillomavirus types detected with a general PCR method suitable for analysis of cutaneous tumours and normal skin. J Gen Virol 1999; 80:2437-2443.
24. Rector A, Tachezy R, Van Ranst M. A sequence-independent strategy for detection and cloning of circular DNA virus genomes by using multiply primed rolling-circle amplification. J Virol 2004; 78: 4993-4998.
25. Jit M, Choi YH, Edmunds WJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 2008; 337:a769.
26. Aubin F, Pretet JL, Jacquard AC, et al. Human papillomavirus genotype distribution in external acuminata condylomata: A large French national study (EDiTH IV). Clin Infect Dis 2008; 47:610-615.
27. Vandepapeliere P, Barrasso R, Meijer CJ, et al. Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: Infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination. J Infect Dis 2005; 192:2099-2107.
28. Read TR, Hocking JS, Chen MY, et al. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect 2011; 87:544-547.
29. Chan PK, Luk AC, Luk TN, et al. Distribution of human papillomavirus types in anogenital warts of men. J Clin Virol 2009; 44: 111-114.
30. Greer CE, Wheeler CM, Ladner MB, et al. Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts. J Clin Microbiol 1995; 33:2058-2063.